A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse

PURPOSE: Hormone receptor-positive (HR+) breast cancer is clinically and biologically heterogeneous and subgroups with different prognostic and treatment sensitivities need to be identified. EXPERIMENTAL DESIGN: Research-based PAM50 subtyping and expression of additional genes was performed on 63 pa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Prat, Aleix, Lluch, Ana, Turnbull, Arran K., Dunbier, Anita K., Calvo, Lourdes, Albanell, Joan, de la Haba-Rodríguez, Juan, Arcusa, Angels, Chacón, José Ignacio, Sánchez-Rovira, Pedro, Plazaola, Arrate, Muñoz, Montserrat, Paré, Laia, Parker, Joel S., Ribelles, Nuria, Jimenez, Begoña, Bin Aiderus, Abdul Aziz, Caballero, Rosalía, Adamo, Barbara, Dowsett, Mitch, Carrasco, Eva, Martín, Miguel, Dixon, J. Michael, Perou, Charles M., Alba, Emilio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5449267/
https://ncbi.nlm.nih.gov/pubmed/27903675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2092
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller